TGF-β has been shown to affect anti-PD-1/PD-L1 immunotherapy by inhibiting the activation of T-cell and by inducing PD-L1 upregulation in tumor cells and tumor-associated angiogenesis. This evidence concerns the gene PDCD1 and neoplasm.